You are here: Industry Insights > Semaglutide

News List

Novo Nordisk's AM833 shows early success in obesity trials pharmatimes
June 22, 2020
Novo Nordisk has unveiled headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue (AM833) - a Phase II monotherapy trial and a Phase I combination trial of AM833 and once-weekly subcutaneous semaglutide.
With the Approval of World’s First Oral GLP-1 Receptor Agonist, Novo Nordisk Maintains its Dominance in the Diabetes Area PharmaSources/Dopine
October 25, 2019
FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form on Sept. 20th.With the approval of this world’s first Oral GLP-1 Receptor Agonist, Novo Nordisk maintains its dominance in the diabetes area.
FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes drugs
September 23, 2019
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).
Oral Semaglutide Reduces HbA1c, Weight in Patients With T2DM drugs
August 01, 2019
Compared with placebo, oral semaglutide monotherapy is associated with superior and clinically relevant improvements in glycated hemoglobin (HbA1c) ...
Application to EMA filed for the approval of oral semaglutide europeanpharmaceuticalreview
April 30, 2019
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill fiercepharma
October 29, 2018
Novo Nordisk rolled out its latest set of data for its next great hope: the oral version of semaglutide, which would become the only pill in the increasingly competitive GLP-1 class.
Novo's semaglutide hits the mark in Phase 3 type 2 diabetes study pharmafile
August 22, 2018
Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of adult patients with type 2 diabetes and moderate renal impairment......
Novo has a big pricing decision to make with semaglutide. Which way will it go? fiercepharma
August 14, 2018
As Novo Nordisk’s highly anticipated semaglutide pill nears the market, the company has a big decision to make: at what price?
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction pharmatimes
July 05, 2018
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia fiercepharma
June 25, 2018
Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.

Previous page 1 2 3 4 Next page